KRAS ACTIVATING MUTATION
Clinical trials for KRAS ACTIVATING MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS ACTIVATING MUTATION trials appear
Sign up with your email to follow new studies for KRAS ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for pancreatic cancer: drug cocktail shows promise in early trial
Disease control OngoingThis study tests a combination of four drugs—two standard chemotherapy drugs plus two experimental ones—in people with advanced pancreatic cancer that has spread. The goal is to see if this mix is safe and can shrink tumors. About 40 adults who haven't had treatment yet will take…
Matched conditions: KRAS ACTIVATING MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New drug cocktail targets hard-to-treat lung cancer mutation
Disease control OngoingThis study tests a combination of two or three experimental drugs (avutometinib, sotorasib, and defactinib) in people with a specific type of advanced lung cancer called KRAS G12C non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the …
Matched conditions: KRAS ACTIVATING MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated May 15, 2026 12:07 UTC